Abbott Laboratories (NYSE:ABT) insider Daniel Gesua Sive Salvadori sold 71,157 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $55.00, for a total transaction of $3,913,635.00. Following the completion of the sale, the insider now directly owns 144,955 shares of the company’s stock, valued at approximately $7,972,525. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Daniel Gesua Sive Salvadori also recently made the following trade(s):
- On Monday, October 23rd, Daniel Gesua Sive Salvadori sold 96,603 shares of Abbott Laboratories stock. The stock was sold at an average price of $56.21, for a total transaction of $5,430,054.63.
- On Tuesday, September 26th, Daniel Gesua Sive Salvadori sold 62,460 shares of Abbott Laboratories stock. The shares were sold at an average price of $52.95, for a total transaction of $3,307,257.00.
Abbott Laboratories (ABT) traded down $1.27 during mid-day trading on Monday, hitting $54.71. The stock had a trading volume of 4,588,908 shares, compared to its average volume of 6,614,972. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. Abbott Laboratories has a 1-year low of $37.42 and a 1-year high of $56.69. The firm has a market capitalization of $95,230.00, a P/E ratio of 23.23, a P/E/G ratio of 2.10 and a beta of 1.55.
Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The firm had revenue of $6.83 billion during the quarter, compared to analysts’ expectations of $6.72 billion. During the same quarter in the prior year, the business posted $0.59 earnings per share. Abbott Laboratories’s revenue was up 28.8% compared to the same quarter last year. equities research analysts expect that Abbott Laboratories will post 2.49 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were given a $0.265 dividend. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.94%. The ex-dividend date of this dividend was Thursday, October 12th. Abbott Laboratories’s dividend payout ratio is currently 87.60%.
Several hedge funds have recently made changes to their positions in ABT. Vanguard Group Inc. increased its position in Abbott Laboratories by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock worth $6,308,944,000 after purchasing an additional 3,241,063 shares in the last quarter. State Street Corp increased its position in Abbott Laboratories by 18.9% during the 1st quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock worth $3,574,987,000 after purchasing an additional 12,806,535 shares in the last quarter. Capital Research Global Investors boosted its stake in Abbott Laboratories by 45.7% in the 2nd quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock worth $2,313,334,000 after buying an additional 14,918,038 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Abbott Laboratories by 11.0% in the 1st quarter. Bank of New York Mellon Corp now owns 33,796,869 shares of the healthcare product maker’s stock worth $1,500,920,000 after buying an additional 3,344,508 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Abbott Laboratories by 3.1% in the 2nd quarter. Northern Trust Corp now owns 26,865,706 shares of the healthcare product maker’s stock worth $1,305,942,000 after buying an additional 809,732 shares during the last quarter. Institutional investors and hedge funds own 71.01% of the company’s stock.
Several brokerages have recently weighed in on ABT. ValuEngine cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Friday. Barclays boosted their price target on shares of Abbott Laboratories from $57.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, September 28th. Zacks Investment Research lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. BMO Capital Markets restated a “hold” rating and set a $53.00 target price on shares of Abbott Laboratories in a research note on Monday, October 2nd. Finally, Stifel Nicolaus upped their target price on shares of Abbott Laboratories from $58.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, October 19th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $56.81.
COPYRIGHT VIOLATION WARNING: “Abbott Laboratories (ABT) Insider Sells $3,913,635.00 in Stock” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/12/04/abbott-laboratories-abt-insider-sells-3913635-00-in-stock.html.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.